Skip to main content

Corcept Therapeutics Incorporated

corporate_fare Company Profile

Corcept Therapeutics Incorporated

CORT·NASDAQ·Life Sciences·CIK 0001088856

We are a commercial-stage company focused on discovering and developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by adjusting the effects of the hormone cortisol. Cortisol is crucial for the body's stress response, metabolism, immune system, and emotional stability, with levels naturally peaking upon awakening and decreasing throughout the day. We address both insufficient cortisol activity, which can cause dehydration, hypotension, shock, fatigue, and hypoglycemia, and excessive cortisol activity, known as hypercortisolism. Hypercortisolism can lead to hypertension, diabetes, impaired glucose tolerance, obesity, fatty liver disease, depressed mood, psychosis, wasting of limbs, edema, fatigue, and insomnia. Cortisol also impacts cancer by reducing immune response to oncogenesis, protecting certain cancer cells from chemotherapy, and promoting the growth of others. Pre-clinical and clinical data suggest that modulating cortisol activity may improve outcomes for patients with fatty liver disease and metabolic dysfunction-associated steatohepatitis ("MASH"), which can lead to liver fibrosis and cirrhosis. Data also indicate potential treatments for patients with amyotrophic lateral sclerosis ("ALS") through cortisol modulation. Since 2012, we have marketed Korlym in the United States for treating hypercortisolism (Cushing's syndrome). In June 2024, we launched an authorized generic version of Korlym for the same condition. Korlym's active ingredient, mifepristone, works by competing with cortisol for binding to the glucocorticoid receptor ("GR"), effectively modulating the effects of abnormal cortisol levels and release patterns without disrupting healthy cortisol functions or rhythms.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CORT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CORT spans 10-Q, 8-K, DEF 14A.

Recent high-impact activity:

  • Corcept 10-Q: Q3 Revenue $340.5M, Net Income $126.8M, Buyback Nearly Exhausted
  • Q3 Revenue Jumps 64% to $340.5M as Lifyorli Launch Accelerates; Guidance Reiterated
  • BELLA Triplet Data Show 7.2-Month PFS in Platinum-Resistant Ovarian Cancer
  • ADA/EASD Guidelines Back T2D Screening for Hypercortisolism, Citing Corcept's Mifepristone Data
  • CHMP Backs EU Approval for Corcept's Lifyorli in Ovarian Cancer

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$761.41M
Net Income
$99.65M
Diluted EPS
$0.82
Op. Cash Flow
$142M
Free Cash Flow
$141.78M
Gross Profit
$748.43M
Operating Income
$44.8M
Cash & Equivalents
$120.5M
Debt / Equity
0.00×
Net Margin
13.1%
Shares Outstanding
105.97M sh
Source: 10-K · filed 2026-02-24 · accession 0001628280-26-011091

Short Interest & Short Volume

8.10 days to cover

FINRA reported short interest of 9,125,717 shares in CORT as of the October 30, 2026 settlement, a 6.3% increase from the prior period — about 8.1 days to cover at its recent average daily volume. On November 20, 2026, 56.4% of CORT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)9,125,717 shares as of October 30, 2026
Change vs prior period▲ 6.3%
Days to cover8.10 at avg daily volume of 1,125,986
Daily short volume (FINRA facilities)56.4% of 402,233 shares on November 20, 2026
5-day average short volume55.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CORT, detected from its recent SEC filings · based on capital-structure filings through 2026-05-28.

Incentive Plan Share Increase Approved · Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$63.62
52-week range · as of 2026-11-03 $28.66 – $126.38
Market cap
$6.96B
Volume
1.1M (1.0× avg)
3-mo avg 1.1M
Live data · 2026-11-22 06:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CORT - Latest Insights

CORT
Nov 03, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $78.50
Real-time Price: $63.62 info
Change: -$14.88 (-19%) info
Market Cap: $6.963B info
CORT
Nov 03, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $81.93
Real-time Price: $63.62 info
Change: -$18.31 (-22%) info
Market Cap: $6.963B info
CORT
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $86.01
Real-time Price: $63.62 info
Change: -$22.39 (-26%) info
Market Cap: $6.963B info
CORT
Oct 20, 2026, 4:00 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $116.51
Real-time Price: $63.62 info
Change: -$52.89 (-45%) info
Market Cap: $6.963B info
CORT
Sep 18, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $114.90
Real-time Price: $63.62 info
Change: -$51.28 (-45%) info
Market Cap: $6.963B info
CORT
Jul 29, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $112.56
Real-time Price: $63.62 info
Change: -$48.94 (-43%) info
Market Cap: $6.963B info
CORT
Jul 29, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $110.00
Real-time Price: $63.62 info
Change: -$46.38 (-42%) info
Market Cap: $6.963B info
CORT
Jun 17, 2026, 4:43 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $81.75
Real-time Price: $63.62 info
Change: -$18.13 (-22%) info
Market Cap: $6.963B info
CORT
Jun 17, 2026, 4:36 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $81.75
Real-time Price: $63.62 info
Change: -$18.13 (-22%) info
Market Cap: $6.963B info
CORT
Jun 03, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $70.00
Real-time Price: $63.62 info
Change: -$6.38 (-9%) info
Market Cap: $6.963B info
CORT
Jun 03, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.00
Real-time Price: $63.62 info
Change: -$6.38 (-9%) info
Market Cap: $6.963B info
CORT
May 28, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $68.38
Real-time Price: $63.62 info
Change: -$4.76 (-7%) info
Market Cap: $6.963B info
CORT
May 27, 2026, 8:18 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $64.00
Real-time Price: $63.62 info
Change: -$0.380 (-0.59%) info
Market Cap: $6.963B info
CORT
May 01, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $46.99
Real-time Price: $63.62 info
Change: +$16.63 (+35%) info
Market Cap: $6.963B info
CORT
Apr 30, 2026, 6:47 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $47.00
Real-time Price: $63.62 info
Change: +$16.62 (+35%) info
Market Cap: $6.963B info
CORT
Apr 30, 2026, 4:34 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $46.99
Real-time Price: $63.62 info
Change: +$16.63 (+35%) info
Market Cap: $6.963B info
CORT
Apr 17, 2026, 4:08 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $46.16
Real-time Price: $63.62 info
Change: +$17.46 (+38%) info
Market Cap: $6.963B info
CORT
Mar 25, 2026, 1:31 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $41.08
Real-time Price: $63.62 info
Change: +$22.54 (+55%) info
Market Cap: $6.963B info
CORT
Mar 25, 2026, 10:59 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $46.98
Real-time Price: $63.62 info
Change: +$16.64 (+35%) info
Market Cap: $6.963B info
CORT
Mar 23, 2026, 9:05 PM EDT
Source: Access Newswire
Importance Score:
7
Price at Filing: $34.00
Real-time Price: $63.62 info
Change: +$29.62 (+87%) info
Market Cap: $6.963B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets